Feed FOLD
FO

Amicus Therapeutics FOLD NASDAQ · Healthcare · United States

$14.49 +0.00% +$0.00

Summary

24 / 100 · Bulios Score

What speaks for it

  • Revenue grew by 15% a year over the last 3 years.
  • The price moves less than the market (beta 0.48).

What to watch

  • The company made a loss over the last 12 months.
  • Operating profit does not even cover the interest on its debt.
  • It passes only 3 of the 9 points of the Piotroski financial health test.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

Slowly

Revenue (USD)

  • Analyst estimate

Revenue grew by 19% a year over 5 years. Over the last 3 years it grew by 15% a year.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Yes

It holds more cash than debt. The debt score is low because of the debt-to-equity ratio (1.6x).

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

67% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

This revenue breakdown is on the way.

By region

This revenue breakdown is on the way.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy